State Of Alaska, Department Of Revenue Uni Qure N.V. Transaction History

State Of Alaska, Department Of Revenue

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 24, 2023	SELL	$11.12 - $22.2 $7,328 - $14,629	-659 Reduced 2.34%	27,552 $315,000
Q1 2023 Apr 17, 2023	SELL	$18.7 - $23.07 $8,882 - $10,958	-475 Reduced 1.66%	28,211 $568,000
Q4 2022 Jan 11, 2023	BUY	$18.12 - $27.32 $3,913 - $5,901	216 Added 0.76%	28,686 $650,000
Q3 2022 Oct 20, 2022	BUY	$16.98 - $25.54 $16,555 - $24,901	975 Added 3.55%	28,470 $534,000
Q2 2022 Jul 08, 2022	BUY	$13.15 - $20.45 $31,823 - $49,489	2,420 Added 9.65%	27,495 $512,000
Q1 2022 Apr 14, 2022	SELL	$14.54 - $21.5 $6,397 - $9,460	-440 Reduced 1.72%	25,075 $453,000
Q4 2021 Jan 12, 2022	SELL	$20.24 - $36.01 $14,167 - $25,207	-700 Reduced 2.67%	25,515 $529,000
Q3 2021 Oct 07, 2021	BUY	$26.01 - $38.22 $681,852 - $1 Million	26,215 New	26,215 $839,000

142

35.3M

1.54M

389K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $300M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of State Of Alaska, Department Of Revenue, based on Form 13F filings with the SEC.

Stay updated on State Of Alaska, Department Of Revenue with notifications on news.